Neurocrine Biosciences, Inc. (NASDAQ:NBIX) saw a significant growth in short interest in November. As of November 29th, there was short interest totalling 4,340,000 shares, a growth of 11.6% from the November 14th total of 3,890,000 shares. Based on an average trading volume of 833,200 shares, the short-interest ratio is currently 5.2 days. Approximately 4.8% of the company’s stock are short sold.
Shares of NBIX stock traded down $0.84 during trading hours on Friday, hitting $110.59. 1,511,551 shares of the company were exchanged, compared to its average volume of 1,099,549. The company has a debt-to-equity ratio of 0.83, a quick ratio of 6.99 and a current ratio of 7.08. Neurocrine Biosciences has a one year low of $66.71 and a one year high of $119.65. The business’s 50-day simple moving average is $110.05 and its two-hundred day simple moving average is $95.60. The stock has a market capitalization of $10.43 billion, a price-to-earnings ratio of 492.39, a P/E/G ratio of 5.73 and a beta of 1.24.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.56 EPS for the quarter, missing the consensus estimate of $0.63 by ($0.07). Neurocrine Biosciences had a return on equity of 5.67% and a net margin of 3.12%. The company had revenue of $222.09 million for the quarter, compared to the consensus estimate of $211.31 million. During the same period in the previous year, the business posted $0.52 EPS. The business’s revenue for the quarter was up 46.3% on a year-over-year basis. As a group, analysts anticipate that Neurocrine Biosciences will post 0.82 EPS for the current fiscal year.
In other news, CFO Matt Abernethy sold 1,645 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $116.33, for a total transaction of $191,362.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Julie Cooke sold 987 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $88.56, for a total value of $87,408.72. The disclosure for this sale can be found here. Insiders have sold 47,776 shares of company stock valued at $4,936,638 over the last 90 days. Insiders own 4.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC lifted its holdings in Neurocrine Biosciences by 6.1% in the second quarter. Janus Henderson Group PLC now owns 9,352,240 shares of the company’s stock worth $789,610,000 after acquiring an additional 540,279 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in Neurocrine Biosciences by 7.1% in the second quarter. Perceptive Advisors LLC now owns 4,023,862 shares of the company’s stock worth $339,734,000 after acquiring an additional 265,200 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in Neurocrine Biosciences by 189.4% in the second quarter. Point72 Asset Management L.P. now owns 1,124,684 shares of the company’s stock worth $94,957,000 after acquiring an additional 735,992 shares during the last quarter. Pictet Asset Management Ltd. lifted its holdings in Neurocrine Biosciences by 9.6% in the third quarter. Pictet Asset Management Ltd. now owns 1,041,000 shares of the company’s stock worth $93,805,000 after acquiring an additional 91,310 shares during the last quarter. Finally, Nuveen Asset Management LLC bought a new position in Neurocrine Biosciences in the second quarter worth about $64,739,000. 97.15% of the stock is currently owned by hedge funds and other institutional investors.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.